Navigation Links
Neurocrine Biosciences Reports Second Quarter 2014 Results
Date:8/6/2014

am in Tourette syndrome patients this year.

Elagolix UpdateAbbVie is currently conducting the Violet Petal Study, a Phase III study of elagolix for endometriosis.  The study is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain.  Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study which completed patient recruitment and randomization during the second quarter.

AbbVie is also conducting the second Phase III study of elagolix for endometriosis, the Solstice Study.  This study is similar in design to the Violet Petal Study and will assess 788 women, age 18 to 49, with moderate to severe endometriosis-associated pain at more than 200 sites globally.

Elagolix is also being studied for utilization in uterine fibroids.  AbbVie is conducting a Phase IIb clinical trial evaluating the change in uterine blood loss of 520 women, age 18-51, with heavy uterine bleeding due to uterine fibroids.

Conference Call and Webcast Tomorrow at 8:00AM Eastern Time
Neurocrine will hold a live conference call and webcast tomorrow at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).  Participants can access the live conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) using the conference ID: NBIX.  The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at ir@neurocrine.com.  A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-839-
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  Colorado and ... have legalized adult use of cannabis. Oregon ... D.C. ended prohibition during the November 2014 elections. ... Photo - http://photos.prnewswire.com/prnh/20141212/164153LOGO The benefits ... noted and obvious benefits like the increased tax revenue for ...
(Date:12/15/2014)... 2014   DaVita HealthCare Partners Inc.  (NYSE: ... largest and most innovative health care communities, today ... DaVita Clinical Research  (DCR) and  HealthCare Partners Clinical Research ... extensive clinical research and data analytics services, specifically ... end-stage renal disease (ESRD), as well as primary ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs ... list of health conditions, drug developers have increasingly ... administration process and increase the efficiency and reliability ...
Breaking Medicine Technology:CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4
... ( US HIFU ), a world leader in minimally invasive ... ) technologies and manufacturer of the Sonablate® 500 medical device ... available to prostate cancer patients for the first ... Curitiba, capital city of the state of Parana in southern ...
... Medical, Inc. ("Kips Bay"), a development stage medical device ... vein support technology, or eSVS MESH, for use in ... it has closed its previously announced offering of 2,062,500 ... $8.00 per share.   Kips Bay ...
Cached Medicine Technology:Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 2Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 3Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 4Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock 2
(Date:12/17/2014)... This prestigious award is given annually ... outstanding and innovative contributions to the physical therapy ... practice physical therapy by the Private Practice Section ... behalf of Performance Physical Therapy, Michelle Collie PT, ... accepted the award at the Private Practice, APTA ...
(Date:12/17/2014)... 17, 2014 No matter how far ... to eradicate the head louse parasite—a common childhood malady ... Each year between six and twelve million individuals will ... lice removal treatment company comes to the rescue, providing ... friendly. With its track record of customer service, and ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... one worrisome phenomenon is when an illness that originated in ... as zoonosis -- is not uncommon and keeps researchers on ... disease might make inroads into the human population. A ... the culprits in this case were guinea pigs. More specifically, ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, ... approaching, a new study reveals that states that routinely perform ... drivers on their roads. The finding suggests that states ... to deter inebriated revelers from getting behind the wheel in ... passed regarding drinking and driving," said study lead author James ...
(Date:12/15/2014)... Cancer researchers have just published an ... of deadly malignant pleural mesothelioma. Surviving Mesothelioma has just ... Click here to read it now. , ... Center, and New York’s Langone Medical Center performed complete ... in an effort to pinpoint the genes that ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2
... Repetitive magnetic stimulation of the brain (rTMS) is considered as ... is found to improve patient movement on the side of ... research it is found that the unaffected side of the ... signals to the affected side that actually impair the patient's ...
... Researchers have concluded that earlier a deaf child receives cochlear implants ... and use of words//. ,When a 3? year-old child, ... in nine months earlier, the right time to make use of ... who had a cochlear implant 31 months earlier made more sophisticated ...
... its policy of short-term solutions a trade union has launched ... that fewer than one in five graduating student nurses would ... forced to recruit overseas to meet workforce targets because of ... guaranteed students a job once they qualify after three years ...
... who are regular with their intake of medications, even if ... those //who don’t adhere to any pattern, according to Canadian ... researchers observe its effects on groups of participants, who are ... into the fray if it scores better in treatment during ...
... used against two of the world's most lethal viruses namely ... that it would be possible to create cheap vaccines that ... is a very large need but no funds available to ... that Rurik Salyaev, of the Siberian Institute of Plant Physiology ...
... health bosses who have told staff to leave corpses on ... hospital bed for four days//, lashed out at them saying ... cash-strapped bosses are not paying for enough night porters to ... ,While an NHS chief confirmed that a body ...
Cached Medicine News:Health News:Earlier the Cochlear Implants Used Better the Speech 2Health News:Earlier the Cochlear Implants Used Better the Speech 3Health News:Nurses Face Unemployment 2Health News:Dead Body on Hospital Bed for Four Days 2
This cannula is flanged with radiopaque tip with 2 side holes....
This cannula features a PVC body, auto inflatable smooth cuff, pressure monitoring line with integral stopcock....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
The DLP Elongated One-Piece Arterial Cannulae features a longer body for easier access during conventional and minimally invasive procedures...
Medicine Products: